Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Gains from Sales and Divestitures (2018 - 2025)

Theravance Biopharma (TBPH) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $336744.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 13.27% to $336744.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $336744.0, a 13.27% increase, with the full-year FY2024 number at $1.6 million, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $336744.0 for Q3 2025 at Theravance Biopharma, down from $413240.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $3.8 million in Q4 2022 to a low of $297284.0 in Q3 2024.
  • A 3-year average of $1.0 million and a median of $516133.0 in 2025 define the central range for Gains from Sales and Divestitures.
  • Biggest YoY gain for Gains from Sales and Divestitures was 15.74% in 2025; the steepest drop was 5.7% in 2025.
  • Theravance Biopharma's Gains from Sales and Divestitures stood at $3.8 million in 2022, then crashed by 56.45% to $1.6 million in 2024, then crashed by 79.47% to $336744.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Gains from Sales and Divestitures are $336744.0 (Q3 2025), $413240.0 (Q2 2025), and $619026.0 (Q1 2025).